The phase 1b WHV138 Safety Review Board (SMB) recently held their second of three period safety review meetings. The board chair, Dr. Marnie Elizaga, together with board members, Dr. Michael Keefer and Dr. Yunda Huang, as well as our study statistician Dr. Sue Li, reviewed cumulative safety data unblinded as to treatment/placebo arm and concluded that the trial can continue without any modifications based on the low-risk safety data. Overall, the trial is progressing well and already in its final stage, the 12-month post-final vaccination follow-up period. With the recent administration of the trial’s final vaccination, the third milestone for the next periodic safety review by the SMB has been met and will be conducted within the next couple of months.
